When JW van Zyl Inc is engaged · 04
Acquiring or investing in a regulated South African healthcare business.
A buyer, investor or partner is evaluating a South African healthcare or life-sciences target, and commercial diligence is being handled elsewhere. The legal and regulatory diligence needs someone who understands both the deal architecture and the regulated environment the target operates in. The risks that kill this class of deal, surviving product liability, non-transferable regulatory permits, unresolved SAHPRA correspondence, an unfixed POPIA position and employment obligations in regulated roles, do not appear on a generic corporate checklist.
Who this is for
Healthcare investors, acquirers, manufacturers and their transaction counsel
Typically instructed by: Corporate development · investment teams · in-house legal · lead transaction counsel
What tends to go wrong
Where this workstream fails without South African counsel
- Regulatory permits are assumed to transfer and do not.
- Product-liability exposure survives closing in ways the sale agreement does not address.
- Historic SAHPRA correspondence is not reviewed and surfaces after completion.
- The POPIA compliance state is not diligenced and arrives with an unbudgeted remediation cost.
- Distribution contracts carry change-of-control clauses that require consents nobody sought.
Scope
What JW van Zyl Inc owns in this workstream
- Regulatory diligence
- The target's SAHPRA, SAPC, Department of Health and industry-code position, including open correspondence, conditions and pending renewals.
- Commercial contract diligence
- Key contracts prioritised by material-adverse-change and change-of-control risk, not by volume.
- Product liability and warranty
- A map of the product-liability and warranty exposure that survives completion, and how it is insured.
- POPIA state
- The current compliance position and an estimate of what remediation will cost the buyer after closing.
- Employment in regulated roles
- Diligence on the appointments the licences and authorisations depend on.
- Diligence report
- Structured to what the negotiating team needs to price and paper the deal, with regulatory risk allocated expressly in the warranties and indemnities.
Outside this workstream
What the firm does not take on here
- Leading the deal negotiation.
- Tax structuring.
- Substantive competition analysis, which is referred to specialist counsel.
How the workstream is instructed
Discovery, scoping, engagement
- Discovery. You identify the target, the deal structure under consideration, the timetable and the diligence already under way elsewhere.
- Scoping. The firm runs a conflicts check against the target and the other parties, and agrees the diligence scope and reporting format.
- Engagement. Scope, deliverables, fees and timelines are agreed in writing before data-room access is taken up.
Timing and fee shapeA regulatory and legal diligence exercise is engaged as a fixed fee for the agreed scope, with a bounded hourly estimate for negotiation support that follows the report. The timetable is set by the deal.
Illustrative situations from prior professional experience are available on request. Anonymised matters comparable to this work are listed under Experience.
Before you instruct
What helps the firm assess the matter
- The target and the other parties to the transaction, for the conflicts check.
- The deal structure under consideration and the timetable.
- The regulated activities the target carries on, and the licences it holds.
- The diligence workstreams already assigned elsewhere.
Free tool
Before you instruct, work through the checklist
Use the Healthcare M&A regulatory due-diligence checklist · the exposure a standard review misses.